RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA
Clinical trials for RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo therapy aims to control hard-to-treat pancreatic cancer
Disease control TerminatedThis early-phase study tests a drug called NBTXR3, which is activated by radiation, in people with pancreatic cancer that is locally advanced or borderline resectable. The goal is to find a safe dose and see if it helps control the disease. About 24 adults will take part, and the…
Matched conditions: RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 18, 2026 12:01 UTC
-
Promising pancreatic cancer study pulled before it began
Knowledge-focused TerminatedThis study aimed to test new therapies for people with pancreatic cancer that hasn't spread. It was designed to compare experimental treatments against standard chemotherapy in three groups based on how far the cancer had grown. However, the study was withdrawn before enrolling a…
Matched conditions: RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated May 22, 2026 13:55 UTC